2010

Gene-gene interactions lead to higher risk for development of type 2 diabetes in an Ashkenazi Jewish population

Rosalind J. Neuman
Washington University School of Medicine in St. Louis

Jon Wasson
Washington University School of Medicine in St. Louis

Gil Atzmon
Albert Einstein College of Medicine

Julio Wainstein
The E. Wolfson Medical Center, Holon, Israel

Yair Yerushalmi
Clalit Health Organization, Tel-Aviv, Israel

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Part of the Medicine and Health Sciences Commons

Recommended Citation
Neuman, Rosalind J.; Wasson, Jon; Atzmon, Gil; Wainstein, Julio; Yerushalmi, Yair; Cohen, Joseph; Barzilai, Nir; Blech, Ilana; Glaser, Benjamin; and Permutt, M. Alan, "Gene-gene interactions lead to higher risk for development of type 2 diabetes in an Ashkenazi Jewish population." PLoS One. 5,3. e9903. (2010).
https://digitalcommons.wustl.edu/open_access_pubs/726

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Rosalind J. Neuman, Jon Wasson, Gil Atzmon, Julio Wainstein, Yair Yerushalmi, Joseph Cohen, Nir Barzilai, Ilana Blech, Benjamin Glaser, and M. Alan Permutt
Gene-Gene Interactions Lead to Higher Risk for Development of Type 2 Diabetes in an Ashkenazi Jewish Population

Rosalind J. Neuman1,2*, Jon Wasson3, Gil Atzmon4, Julio Wainstein6, Yair Yerushalmi7, Joseph Cohen8, Nir Barzilai4, Ilana Blech5, Benjamin Glaser5, M. Alan Permutt3
1 Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, United States of America, 3 Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America, 4 Institute of Aging, Department of Medicine and Genetics, Albert Einstein College of Medicine, New York, New York, United States of America, 5 Endocrinology and Metabolism Service, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, 6 Diabetes Unit, The E. Wolfson Medical Center, Holon, Israel, 7 Endocrinology Unit, Clalit Health Organization, Tel-Aviv, Israel, 8 Diabetes Clinic, Macabbi Health Service, Tel Aviv, Israel

Abstract

Background: Evidence has accumulated that multiple genetic and environmental factors play important roles in determining susceptibility to type 2 diabetes (T2D). Although variants from candidate genes have become prime targets for genetic analysis, few studies have considered their interplay. Our goal was to evaluate interactions among SNPs within genes frequently identified as associated with T2D.

Methods/Principal Findings: Logistic regression was used to study interactions among 4 SNPs, one each from HNF4A[rs1884613], TCF7L2[rs12255372], WFS1[rs10010131], and KCNJ11[rs5219] in a case-control Ashkenazi sample of 974 diabetic subjects and 896 controls. Nonparametric multifactor dimensionality reduction (MDR) and generalized MDR (GMDR) were used to confirm findings from the logistic regression analysis. HNF4A and WFS1 SNPs were associated with T2D in logistic regression analyses [P<0.0001, P<0.0002, respectively]. Interaction between these SNPs was also strong using parametric or nonparametric methods: the unadjusted odds of being affected with T2D was 3 times greater in subjects with the HNF4A and WFS1 risk alleles than those without either (95% CI = [1.7–5.3]; P<0.0001). Although the univariate association between the TCF7L2 SNP and T2D was relatively modest [P = 0.02], when paired with the HNF4A SNP, the OR for subjects with risk alleles in both SNPs was 2.4 [95% CI = 1.7–3.4; P=0.0001]. The KCNJ11 variant reached significance only when paired with either the HNF4A or WFS1 SNPs: unadjusted ORs were 2.0 [95% CI = 1.4–2.8; P=0.0001] and 2.3 [95% CI = 1.2–4.4; P=0.0001], respectively. MDR and GMDR results were consistent with the parametric findings.

Conclusions: These results provide evidence of strong independent associations between T2D and SNPs in HNF4A and WFS1 and their interaction in our Ashkenazi sample. We also observed an interaction in the nonparametric analysis between the HNF4A and KCNJ11 SNPs (P<0.001), demonstrating that an independently non-significant variant may interact with another variant resulting in an increased disease risk.

Introduction

Type 2 diabetes (T2D) has become one of the leading and fastest growing health problems in the world affecting approximately 10 million Americans and over 170 million individuals worldwide in 2000. By 2030 these estimates are expected to rise to over 30 million in the United States and 366 million worldwide [www.who.int/diabetes/facts/world_figures]. Although its exact etiology is unknown, accumulating evidence recognizes T2D as a quintessential multifactorial disease, resulting from numerous inter-
relatively few candidate gene studies have pursued such studies [5–13]. These studies generally include only those variants in their interaction analyses that have shown some nominal probability of marginal significance (e.g. p<0.05) in previous studies. However, there are genetic models in which variants show no independent association with the trait of interest, but which, in concert with other variants, do provide evidence of interaction effects [14]. This phenomenon has also been studied and documented in animal models [15,16].

In the present study we investigated the importance of gene–gene interaction on type 2 diabetes in a case-control sample of Ashkenazi subjects. Four genes, TCF7L2, HNF4A, KCNJ11, and WFS1, all with strong prior evidence for association with T2D and with credible biological mechanistic effects on T2D, were chosen for analysis. One Single Nucleotide Polymorphism (SNP) was selected for genotyping from each of these four candidate genes based on previous studies in which the SNP was shown to be directly associated with T2D or in high linkage disequilibrium with a SNP identified as associated with T2D. SNPs in the TCF7L2 gene were selected as being the only truly universally T2D positive SNPs that had been identified at the start of this study. Two intronic SNPs in high LD (r² = 0.77) in the TCF7L2 gene, rs12255372 and rs7903146, had been identified as being associated with T2D in at least 49 articles. We chose to genotype rs12255372 in our Ashkenazi population. HNF4A is a transcription factor regulating a network of genes controlling insulin secretion and glucose regulation. Recently we have found the HNF4A SNP, rs1884613, to be strongly associated with T2D in an Ashkenazi case-control sample unrelated to the sample in our current study [17]. Rs1884613 is located upstream of HNF4A and has no known function. The potassium channel gene, KCNJ11 on chromosome 11p15.1, regulates glucose-induced insulin secretion in pancreatic beta cells [18–20]. With the exception of Ashkenazi samples, coding SNP rs5219 (E23K) in KCNJ11 has been consistently associated with T2D populations over many years [21]. We included this SNP in our analysis to determine if its effect might be amplified by interactions with other genes in the Ashkenazi population. Although mutations in the WFS1 gene have long been known to be causal in autosomal recessive Wolfram syndrome [22], recently several studies have implicated WFS1 SNPs also to be associated with T2D [23–26]. Four of the five PubMed citations for T2D studies using rs10010131 found evidence for an association with T2D, including a meta analysis of previous studies from Sweden, Finland, and France, which reported a highly significant finding for this SNP [23]. In addition, rs10010131 was one of 2 intronic WFS1 SNPs in strong disequilibrium (r² = 0.98) found to be significant in a study of T2D in UK and Ashkenazi populations studying genes involved in pancreatic β cell function [25] in both populations. Our multilocus analysis strategy makes use of the traditional parametric approach of logistic regression and the nonparametric method of multifactor dimensionality reduction (MDR) [27].

Methods

Ethics Statement

This study was approved by the local ethics committee of each center where samples were collected: the committee on Research Involving Human Subjects of The Hebrew University-Hadassah Medical School, Jerusalem, Israel; Committee on Clinical Investigations at Albert Einstein College of Medicine; the Human Research Protection Office at Washington University in St. Louis. Written informed consent was obtained from all participants before participation in the study.

Samples

To minimize potential genetic heterogeneity, 1,870 subjects (974 cases, 896 controls) were recruited for a cross-sectional study from the Ashkenazi Jewish population. Blood was drawn from all subjects, and age of diagnosis was determined for cases by questionnaire and review of medical history. Subjects had been determined to have T2D if their fasting glucose was greater than 140 mg/dl on more than 1 occasion or random glucose was greater than 200 mg/dl on at least two occasions [28]. Ashkenazi Jews are a relatively homogeneous population thought to have developed from a founder population approximately 500 years ago [29]. Subjects who self identified as Ashkenazi were accepted into the study only if all four grandparents also self identified as Ashkenazi and were born in Northern or Eastern Europe. Most of the subjects in this study reside in Israel (N = 1,600); the remainder are United States citizens residing in New York City, ascertained from the Einstein Longevity Study [30,31]. The NYC portion of our sample contained, with one exception, only controls. Sex, body mass index (BMI) and current smoking status were available for possible inclusion in the analyses.

DNA samples for the Israeli Ashkenazi subjects were obtained from Dr. Benjamin Glaser and genotyping data from the NYC sample were obtained from Dr. Gil Atzmon. Genotypes for Israeli Ashkenazi SNPs were assessed by PCR amplification of genomic DNA and Pyrosequencing technology (Biotage AB, Uppsala, Sweden) as previously described [32]. Genotypes for the NYC sample were assessed by Pyrosequencing technology (Biotage AB, Uppsala, Sweden) as discussed in [33].

Data Analyses

Exact Hardy Weinberg Equilibrium (HWE) tests were performed for each SNP independently among cases and controls. Logistic regression models (SAS V9.1.3) were used to assess the effects of each of the 4 SNPs on T2D with and without adjusting for sex and body mass index (BMI). Smoking status was available for over 98% of controls, but only 25% of cases and therefore was not included in the data analyses. An additive model was used to code SNPs for the ‘risk’ allele, the allele that increased the probability of being a case. Accordingly, ‘0’ indicated the subject was homozygous for the non-risk allele; the heterozygote was coded ‘1’, and those who were homozygous for the risk allele were coded ‘2’. Interaction effects between SNPs were modeled using four mutually exclusive levels: (1) subjects without either risk allele, (2) subjects with one risk allele in the first SNP but not the risk allele in the second SNP, (3) subjects without the risk allele in the first SNP but with the risk allele in the second SNP, and (4) subjects with both risk alleles. Level (1), was considered the reference group [34,35].

Multifactor dimensionality reduction (MDR, V2.0 Beta 2) was used to verify our interaction results. MDR was initially introduced by Ritchie et al., 2001, [36] as a genetically model-free and non-parametric alternative to logistic regression [27,37]. A benefit of these non-parametric models is minimizing statistical issues that frequently arise when using traditional parametric models such as logistic regression. In particular, the possibility often exists that few or no observations will be assigned to contingency table cells when testing for interactions, thereby invalidating the resulting parameter estimates. Briefly, MDR acts by reducing a set of multiflocus genotypes to one dimension with two groups: a high-risk and a low-risk set of genotypes. A particular multiflocus genotype can be declared to be high-risk if the ratio of number of cases to controls exceeds the proportion of cases in the total sample. By grouping the high-risk multiflocus genotypes together and the low-risk genotypes together, the model
is reduced to one dimension, that is, essentially 1 variable with 2 possible values: high or low risk 2-locus genotypes. Models are evaluated on the testing balanced accuracy statistic (TBA) [30], the cross-validation consistency (CVC) [39], and the statistical significance of the model. The TBA measures how often individuals are correctly classified with respect to their case/control status, and the cross-validation consistency (CVC) evaluates the consistency with which individuals are classified. Heuristically, a satisfactory TBA score is above 0.55 (http://compgen.blogspot.com/2006/12/mdr-101-part-4-results.html). We used 10,000 permutations to determine the statistical significance of the best models. These data were also analyzed using an extension of the MDR algorithm that includes adjustment for covariates, the Generalized Multifactor Dimensionality Reduction (GMDR, V0.7) software package [40].

Results

All SNPs were in Hardy-Weinberg equilibrium \[P>0.23\]. Characteristics of the cases and controls are displayed in Table 1. As expected, BMI was significantly greater among cases than controls \[29.5 \, vs. \, 25.9, \, P=0.0001\]. Although there were significantly more males among cases than controls \[49 \% \, vs. \, 42 \%, \, P=0.002\], the proportion among the controls recruited in Israel versus the U.S. did not differ \[P=0.82\]. The age variable was highly correlated with the diagnosis of T2D; the mean age of examination for controls was 72 (±9.3) years versus 47 (±7.8) years for diagnosis of cases \(p<0.0001\). Accordingly, this variable was not included in the statistical analyses. The average age of cases when ascertained for this study was 64 years. Means and standard deviations for cases’ HbA1c measurements and fasting glucose for controls are displayed in Table 1. HbA1c measures on controls were not recorded since at the time of ascertainment it was not an accepted diagnostic tool. Since glucose is totally controlled by treatment and can vary considerably from day to day, fasting glucose was not measured in the cases.

As seen in Table 2, the genotype frequencies between cases and controls were significantly different for the HNF4A and WFS1 genotypes \(P<0.0001, <0.0008\), respectively]. We note that Ashkenazi cases had a greater excess of heterozygous and homozygous HNF4A genotypes with the risk allele than expected by chance, indicating a dominant mode of inheritance. Conversely, WFS1 case/control genotypes indicate a recessive mode of inheritance. Diverging from the results of multiple recent studies in non-Ashkenazi populations [41], the TCF7L2 genotype frequencies between cases and controls only minimally differed \(P=0.055\), and the KCNJ11 genotypes showed no difference with the diagnostic status of the Ashkenazi subjects \(P<0.055\). The OR and \(P\)-values of the logistic regression analyses on the additive genetic models for each SNP, with and without covariates, are displayed in Table 3. Of the four SNPs genotyped, only the HNF4A and WFS1 SNPs were significant with or without covariates after a Bonferroni correction for multiple tests; the \(P\)-value for rs12255372 in TCF7L2 was 0.02. Table 4 presents the results of models for the interaction effects of the SNPs. The risk of a diagnosis for T2D is greatest in subjects with the genotypes. The risk of a diagnosis for T2D is greatest in subjects with the HNF4A and WFS1 SNP risk alleles versus those with neither risk allele \[OR = 3.0, 95\% \, CI = 1.7–5.3\]. There is no or

**Table 1. Ashkenazi Sample Characteristics.**

| Category          | Cases N = 974 | Controls N = 896 | Cases vs. Controls | Mean ± STD | Mean ± STD | P-value |
|-------------------|---------------|------------------|--------------------|-----------|-----------|---------|
| Age(1)            | 47.1±7.8      | 72.3±9.3         | <0.0001            |
| BMI               | 29.4±5.0      | 25.8±4.2         | <0.0001            |
| Sex (% male)      | 49.5          | 42.2             | 0.0018             |
| Smoking (% Current)| 11.6         | 10.4             | 0.61               |
| Fasting Glucose (mmol/L)(2) | NA   | 92.5±37.3       |                   |
| HbA1c(2)          | 7.9±1.5       | NA               |                   |
| Site (% Israeli)  | 100.0         | 69.9             | <0.0001            |

(1)Age at diagnosis for cases; age at examination for controls.
(2)Fasting Glucose was measured only in controls; HbA1c was measured only in cases.
doi:10.1371/journal.pone.0009903.t001

**Table 2. Case and Control Genotype Frequencies.**

| Gene (rs number) | Genotype | Cases (%) | Controls (%) | X2 df(P value) | MAF | OR[95% CI](1) P-value | OR[95% CI](2) P-value |
|------------------|----------|-----------|---------------|---------------|-----|----------------------|----------------------|
| HNF4A (rs1884613) | CC       | 276(52.5) | 473(66.1)     | 31.2 (<0.0001) | 0.23 | 1.77[1.39–2.24]      | <0.0001              |
| WFS1 (rs10010131)| TT       | 50(9.5)   | 27(3.8)       |               |     |                      |                      |
| TCF7L2 (rs10q25.3)| GG      | 217(37.7) | 332(44.2)     |               |     |                      |                      |
| KCNJ11 (rs5219)  | AA       | 79(13.8)  | 100(11.7)     |               |     |                      |                      |
|                 | AG       | 266(46.4) | 404(47.9)     |               |     |                      |                      |
|                 | GC       | 228(39.8) | 339(40.2)     |               |     |                      |                      |

(1)The ‘risk’ allele for the WFS1 SNP is the major allele, C. The risk allele for all other SNPs is the minor allele.
doi:10.1371/journal.pone.0009903.t002

**Table 3. Associations between SNPs in candidate genes and T2D in the Ashkenazi population.**

| Gene (rs number) | OR[95% CI](1) | P-value | OR[95% CI](2) | P-value |
|------------------|---------------|---------|---------------|---------|
| HNF4A (rs1884613)| 1.69[1.40–2.03]| <0.0001 | 1.77[1.39–2.24]| <0.0001 |
| KCNJ11 (rs5219)  | 1.05[0.90–1.23]| 0.52    | 1.02[0.83–1.26]| 0.83    |
| TCF7L2 (rs12255372)| 1.21[1.03–1.42]| 0.02    | 1.21[1.08–1.49]| 0.07    |
| WFS1 (rs10010131)| 1.34[1.15–1.56]| <0.0002 | 1.30[1.06–1.58]| 0.01    |

(1)Unadjusted.
(2)Adjusted by sex, BMI.
doi:10.1371/journal.pone.0009903.t003
minimal increased risk for type 2 diabetes at these two loci if only one risk allele is present: OR = 1.8 [95% CI = 1.1–3.2] for the presence of the WFS1 risk allele but not the HNF4A risk allele, and OR = 1.8 [95% CI = 0.8–4.1] for the presence of the HNF4A risk allele but not the WFS1 risk allele. As noted in Table 3, the odds of T2D for subjects with the TCF7L2 risk allele was 1.2 times greater for subjects with the TCF7L2 risk allele than those without the risk allele in the single SNP logistic regression model. However, when coupled with either the HNF4A or WFS1 genotype containing at least one risk allele, the unadjusted odds of being affected increased, respectively, to 2.4 and 2.9 times greater for subjects with the TCF7L2 risk allele than those with neither risk allele. There was no evidence for an increased risk for T2D due to the presence of the rs5219 [KCNJ11] risk allele but not the WFS1 risk allele. This was also borne out in the nonparametric joint analysis, contingency table cells that contain few or no observations would result in unstable results, a situation that may occur when interactions are introduced into the model [42]. A significant association with T2D was found: OR = 2.4, CI = [1.5–4.0], P = 0.0006. We also note that the MDR interaction between all four SNPs was not significant without inclusion of sex and BMI. But that increase was extremely modest (P = 0.03).

### Discussion

Our main finding is that genetic interactions modulate the risk for T2D in the Ashkenazi case-control sample. Specifically, the strength of the association between polymorphisms of the HNF4A and WFS1 genes and T2D in the parametric analyses indicated a three fold increased risk of T2D for individuals who carry the risk alleles of these polymorphisms compared to individuals whose genotypes contain neither risk allele. This interaction was also echoed in the MDR/GMDR analysis. Although the TCF7L2 SNP was not strongly associated with T2D in this population, when TCF7L2 was jointly analyzed with either of the HNF4A or WFS1 SNPs, more than a two-fold increase in T2D risk was observed for subjects with both risk alleles. This was also borne out in the nonparametric MDR/GMDR analyses. While this phenomena has been discussed in a theoretical context [14] and has been shown to exist in animal models [15,16], it has not commonly been seen in human studies, particularly one with thousands of variants, such as a GWA study in which any SNPs that are not highly significant are often not included in follow-up interaction or non-interaction studies. In this analysis there was no evidence that the KCNJ11 SNP, rs5219, altered the strength of the association in the parametric analysis when paired with any other candidate SNP. The apparent importance of rs5219 in the nonparametric interaction analysis may have been the result of the presence of rs1884613 [HNF4A] in the interaction models. However, it is difficult to understand the disparity in the significance between the nonparametric HNF4A x KCNJ11 x TCF7L2 interaction (P = 0.001), and the HNF4A x TCF7L2 x WFS1 interaction (P = 0.01) given the significance of the WFS1 versus the KCNJ11 SNPs in the logistic regression analyses. To the best of our knowledge, this is the first time a significant genetic interaction effect associated with T2D was reported in a sample of Ashkenazi Jewish descent.

Among those who have reported on studies involving variants in genes of interest in the current study is Weeden et al., 2006 [13] who examined the relationship among rs5219 in the KCNJ11 gene, rs7903146 in TCF7L2, a SNP in high LD with rs12255372 (r² = 0.75), and Pro12 in the PPARG gene in a sample of over

---

**Table 4. Odds ratios and 95% Confidence Intervals (CIs) for the Joint Effects of Candidate SNP Genotypes on Type 2 Diabetes.**

| Gene Pair | Risk Allele 1 | Risk Allele 2 | OR (95% CI) |
|-----------|--------------|--------------|-------------|
| HNF4A, KCNJ11 | – | – | 1.00 (1.00) |
| rs1884613, s | – | + | 1.21 (0.88–1.66) |
| rs 5219 | + | – | 1.95 (1.34–2.83) |
| HNF4A, TCF7L2 | – | – | 1.00 (1.00) |
| rs1884613, s | – | + | 1.43 (1.05–1.96) |
| rs12255372 | + | – | 1.88 (1.29–2.74) |
| HNF4A, WFS1 | – | – | 1.00 (1.00) |
| rs1884613, s | – | + | 1.82 (1.05–3.17) |
| rs10010131 | + | – | 1.80 (0.78–4.11) |
| KCNJ11, TCF7L2 | – | – | 1.00 (1.00) |
| rs 5219 | – | – | 1.20 (0.87–1.76) |
| rs12255372 | + | – | 1.03 (0.72–1.46) |
| KCNJ11, WFS1 | – | – | 1.00 (1.00) |
| rs 5219 | – | – | 2.32 (1.21–4.46) |
| rs10010131 | + | – | 1.71 (0.74–3.98) |
| TCF7L2, WFS1 | – | – | 1.00 (1.00) |
| rs12255372 | + | – | 2.18 (0.97–4.90) |
| rs10010131 | + | – | 1.60 (0.62–4.09) |
| + | 2.87 (1.28–6.40) |

1) Risk alleles 1 and 2 refer to the leftmost and rightmost genotypes in the ‘Gene Pair’ column. ‘−’ indicates absence of the risk allele; ‘+’ indicates presence of the risk allele; allele1 and allele2 = ‘−’ is the reference group.

2) Unadjusted.

3) Adjusted for Sex, BMI.

doi:10.1371/journal.pone.0009903.t004

---

(see page for table content)
Although no gene-gene interactions were found, a strong positive relationship between the numbers of risk alleles within a subject and risk of T2D was reported: subjects with all six risk alleles had an OR of 5.7 [95% CI = 1.2–28.3] for T2D compared to subjects with no risk alleles. Cauchi et al., 2008 [6] chose 22 SNPs in 14 loci from a previous GWA study to replicate in four independent European samples, including an Israeli Ashkenazi and Moroccan sample. However, they only analyzed interaction effects in the French subset of their sample, and none of their loci overlapped with any of those analyze in the current study. Using MDR, Qi et al. [9] reported an interaction between rs5219 in KCNJ11 and rs2144908 in HNF4A in a case-control study of T2D in a sample of female subjects from the Nurses’ Health Study. We note that rs2144908 is in complete LD with rs1884613, r² = 1. Therefore, our MDR finding of an interaction between rs5219 and rs1884613 in the Ashkenazi sample is a replication of the Qi et al. study. To the best of our knowledge, Qi et al. was the first to report an interaction between SNPs in the HNF4A and KCNJ11 genes.

A strength of the current study is that all subjects with T2D were Ashkenazi Jews living in Israel. Almost 70% of the controls were also ascertained in Israel, with the remainder Ashkenazi Jews from the U.S. No differences were detected between the two groups of controls regarding smoking status, BMI, or gender. By choosing Ashkenazi Jews for both cases and controls, we have minimized the potential of genetic heterogeneity. An additional strength of this study is that the mean age at ascertainment of non-T2D status in the control population was 76 years, whereas the mean age of T2D diagnosis in the cases was 25 years less, adding to the confidence that this control group is not at high risk for a future diagnosis. Furthermore, the average age at diagnosis of the cases was 47 years, relatively young, and therefore more likely to be genetically predisposed to T2D [43].

A major challenge for studies such as ours and those that investigate the interaction between thousands of variants is to decipher the complexity of the genetic networks between the loci that appear to have a statistical relationship [44]. In this study, we know that WFS1 appears to be part of the mechanisms related to beta-cell survival [45], and HNF4a may have proliferative and/or functional effects. The functional effects may interact with survival-increased function resulting in increased endoplasmic reticulum (ER) and/or oxidative stress resulting in increased apoptosis. Inactivating mutations in HNF4a have been shown to cause hyperinsulinemic hypoglycemia during the fetal and newborn period, as well as MODY diabetes in adolescence [46]. We still know very little about whether T2D associated variants effects increased or decreased expression of HNF4A. The mechanism for such effect is still not well understood. Therefore it would be pure speculation to try to explain the interactions found in this study on the basis of known function.

In conclusion, all four chromosomal regions investigated in this study harbor T2D genetic variants that have been replicated in published studies, but very few studies have considered their interactions. Nevertheless, we fully expect that additional variants, some rare, will be added to the growing list of polymorphisms that influence T2D, and that the analyses of interacting variants will lead to a better understanding of the biological pathways underlying T2D. This knowledge will bring us closer to the development of effective prevention and treatment strategies.

### Table 5. Gene x Gene Interaction Models: MDR (without covariates) and GMDR (with covariates).

| Interacting SNPs | Covariates | Number of Subjects | CVC(1) | TBA(2) | 10,000 Permutations P-value |
|------------------|------------|--------------------|--------|--------|-----------------------------|
| HNF4A x KCNJ11   | none       | 1162               | 10/10  | 0.560  | 0.001                       |
|                  | Sex, BMI   |                    | 10/10  | 0.564  | 0.002                       |
| HNF4A x TCF7L2   | none       | 1153               | 10/10  | 0.540  | 0.028                       |
|                  | Sex, BMI   |                    | 10/10  | 0.565  | 0.002                       |
| HNF4A x WFS1     | none       | 1176               | 10/10  | 0.546  | 0.009                       |
|                  | Sex, BMI   |                    | 10/10  | 0.559  | 0.004                       |
| KCNJ11 x TCF7L2  | none       | 1288               | 10/10  | 0.504  | 0.437                       |
|                  | Sex, BMI   |                    | 10/10  | 0.495  | 0.595                       |
| KCNJ11 x WFS1    | none       | 1117               | 10/10  | 0.516  | 0.252                       |
|                  | Sex, BMI   |                    | 10/10  | 0.528  | 0.146                       |
| TCF7L2 x WFS1    | none       | 1111               | 10/10  | 0.546  | 0.010                       |
|                  | Sex, BMI   |                    | 10/10  | 0.535  | 0.090                       |
| HNF4A x KCNJ11 x TCF7L2 | none       | 1122               | 10/10  | 0.565  | 0.001                       |
|                  | Sex, BMI   |                    | 10/10  | 0.546  | 0.040                       |
| HNF4A x KCNJ11 x WFS1 | none       | 1105               | 10/10  | 0.541  | 0.031                       |
|                  | Sex, BMI   |                    | 10/10  | 0.549  | 0.034                       |
| HNF4A x TCF7L2 x WFS1 | none       | 1096               | 10/10  | 0.551  | 0.011                       |
|                  | Sex, BMI   |                    | 10/10  | 0.540  | 0.072                       |
| KCNJ11 x TCF7L2 x WFS1 | none       | 1080               | 10/10  | 0.528  | 0.122                       |
|                  | Sex, BMI   |                    | 10/10  | 0.497  | 0.549                       |
| HNF4A x KCNJ11 x TCF7L2 x WFS1 | none       | 1068               | 10/10  | 0.512  | 0.313                       |
|                  | Sex, BMI   |                    | 10/10  | 0.552  | 0.029                       |

(1) Cross Validation Consistency.  
(2) Testing Balanced Accuracy.

doi:10.1371/journal.pone.0009903.t005
Author Contributions
Conceived and designed the experiments: RJW JG AW YY JC NB IB
BG MAP. Analyzed the data: RJN. Contributed reagents/materials/analysis tools: JW. Wrote the paper: RJN. Revisions and final approval of version to be published: J. Watson J. Waistain. Extensive revisions and final approval of version to be published: GA. Extensive revisions and final approval of version: BG. Revisions and final approval of version: YY JC NB IB MAP.

References

1. Mensink M (2005) Lifestyle intervention, glucose tolerance, and risk of developing type 2 diabetes mellitus. Metab Syndr Related Disord 3: 26–34.
2. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106: 9362–9367.
3. Doria A, Pett DES. (2008) The emerging genetic architecture of type 2 diabetes. Cell Metab 8:180–200.
4. Granz RM, Moore AF, Horvitz JC (2009) Genetic architecture of type 2 diabetes: recent progress and clinical implications. Diabetes Care 32: 1107–1114.
5. Black MH, Fingerlin TE, Allayee H, Zhang W, Xiang AH, et al. (2008) Evidence of interaction between PPARδ and HNF4A contributing to variation in insulin sensitivity in Mexican Americans. Diabetes 57: 1048–1056.
6. Cauchi S, Meyre D, Durand E, Proenca C, Marre M, et al. (2008) Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS One 3: e3031.
7. Hansen SK, Nielsen EM, Ek J, Andersen G, Glumer C, et al. (2005) Analysis of separate and combined effects of common variation in KCNJ11 and PPARγ on risk of type 2 diabetes. J Clin Endocrinol Metab 90: 3629–3637.
8. Miyake K, Yang W, Hara K, Yasuda K, Han Y, et al. (2005) Construction of an eQTL database for type 2 diabetes mellitus in the Japanese population based on 11 genes with strong evidence of the association. J Hum Genet 54: 236–241.
9. Qi L, van Dam RM, Ab meassey FW, Hu FB (2007) Gene-gene interactions between HNF4A and KCNJ11 predicting type 2 diabetes in women. Diabetes Metab Rev 22: 348–361.
10. Hanlon P, Lorenz WA, Shao Z, Harper JM, Galecki AT, et al. (2006) Three-dimensional molecular dynamics studies of a human disease allele reveal a mechanism of genotype-phenotype association. Proc Natl Acad Sci U S A 103: 5300–5305.
11. Barzilai N, Atzmon G, Schachter CB, Schachter EJ, Capples AL, et al. (2003) Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290: 2803–2810.
12. Botto LD, Khoury MJ (2001) Commentary: facing the challenge of gene-environment interaction. Diabetes Care 24: 1187–1191.
13. Evensen TA, Grarup N, Andreassen A, Albrechtsen A, Holmkniv J, et al. (2009) Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. Diabetes 58: 1166–1172.
14. Winkel S, Weedon MN, Graham RR, McCarroll SA, Purcell S, et al. (2007) Replication of the association between variants in WFS1 and risk of type 2 diabetes. Diabetes Metab Res Rev 24: 138–140.
15. Hanlon P, Lorenz WA, Shao Z, Harper JM, Galecki AT, et al. (2006) Reconstruction of a functional human gene network, with an application to prioritizing positional candidate genes. Am J Hum Genet 78: 1011–1025.
16. Jarvis JP, Cheverud JM (2009) Epistasis and the evolutionary dynamics of measured genotypic values during simulated serial bottlenecks. J Evol Biol 22: 1650–1669.
17. Barroso I, Luan J, Wheeler E, Whittaker P, Wasson J, et al. (2008) Population-based genome-wide association study of type 2 diabetes confirms a susceptibility locus on chromosome 6q21 and identifies two new loci on 10q24 and 12q32. Diabetes 57: 2698–2705.
18. Alsmadi O, Al-Rubeaan K, Wakil SM, Imtiaz F, Mohamed G, et al. (2008) Population-based genome-wide association study of type 2 diabetes confirms a susceptibility locus on chromosome 6q21 and identifies two new loci on 10q24 and 12q32. Diabetes 57: 2698–2705.
19. Barroso I, Luan J, Wheeler E, Whittaker P, Wasson J, et al. (2008) Population-based genome-wide association study of type 2 diabetes confirms a susceptibility locus on chromosome 6q21 and identifies two new loci on 10q24 and 12q32. Diabetes 57: 2698–2705.
20. Love-Gregory L, Wasson J, Lin J, Skolnick G, Suarez B, et al. (2003) E23K polymorphism with type 2 diabetes. Diabetes Metab Res Rev 24: 138–140.
21. Frayling TM, Wiltshire S, Hitman GA, Walker M, Levy JC, et al. (2003) Young-onset type 2 diabetes families are the major contributors to genetic loci in the Diabetes UK Warren 2 genome scan and identify putative novel loci on chromosomes 6q21, 21q22, and 22q11. Diabetes 52: 1857–1863.
22. Frayling TM, Wiltshire S, Hitman GA, Walker M, Levy JC, et al. (2003) Young-onset type 2 diabetes families are the major contributors to genetic loci in the Diabetes UK Warren 2 genome scan and identify putative novel loci on chromosomes 6q21, 21q22, and 22q11. Diabetes 52: 1857–1863.
23. Frayling TM, Wiltshire S, Hitman GA, Walker M, Levy JC, et al. (2003) Young-onset type 2 diabetes families are the major contributors to genetic loci in the Diabetes UK Warren 2 genome scan and identify putative novel loci on chromosomes 6q21, 21q22, and 22q11. Diabetes 52: 1857–1863.